However, despite immense interest and serious attempts to clone mitochondrial K ATP channels, their molecular nature remains elusive.
The K ATP channels in the sarcolemma membrane, first described in the heart by Noma (46) in 1983, are widely distributed in many tissues and cell types including pancreatic ␤-cell, neuron, skeletal muscle, and smooth muscle (6, 7) . The major function of the K ATP channel is to couple the cell metabolic state to its membrane potential by sensing changes in intracellular adenine nucleotide concentration (4) . The sarcolemmal K ATP channels are heterooctamers consisting of two structurally unrelated proteins (1, 2, 8, 52, 54) : four pore-lining subunits that belong to the Kir6 subfamily of inwardly rectifying potassium channels and four regulatory subunit sulfonylurea receptors (SUR) of the ATP-binding cassette (ABC) superfamily. It is currently known that the cardiac sarcK ATP channel is composed of an octomeric complex of two types of subunits, the Kir6.2 and the SUR2A subunit.
Whereas the mitoK ATP channel has been characterized pharmacologically (14, 23) , its molecular nature remains unknown. Whether Kir6.2 contributes to mitoK ATP channels is under debate; the subunit has been found in heart mitochondria (15, 36, 56, 74) . We believe that much of the controversy or difficulty regarding the existence of Kir6.2-containing K ATP channels in mitochondria may be due to the low level of basal K ATP channels present in mitochondria. All these studies concerning the existence of Kir6.2-containing K ATP in mitochondria were conducted under basal conditions that do not involve IPC or its signaling molecule(s), a critical step that may upregulate protein transport to mitochondria and thus confer cardioprotection (10) .
Although K ATP channel regulation and implication in cardioprotection have been studied by many groups for years, no study has ever explored the trafficking aspect of K ATP function in mitochondria. The present study utilizing K ATP -deficient COS-7 cells represents a novel approach to elucidation of the molecular basis of the K ATP channels in mitochondria and their regulatory mechanism. We report the novel finding that a protein kinase C (PKC) isozyme, PKC⑀, promotes mitochondrial import of Kir6.2-containing K ATP channels from cytosol, assessed with a combination of immunofluorescence microscopy, Western blot, fluorescence resonance energy transfer (FRET) analysis, and mitochondrial functional studies.
MATERIALS AND METHODS
DNA constructs. The hemagglutinin (HA) epitope was introduced into mouse Kir6.2 cDNA by sequential overlap extension polymerase chain reaction (PCR) as described previously (73) . The epitope was inserted at position 102 of Kir6.2. The 11 amino acids ( 98 GDLYAYMEKGIT 99 ) were inserted into Kir6.2 before the HA epitope. Mammalian expression constructs were either in pcDNA3 (Invitrogen) or pEGFP/pECFP/pEYFP (Clontech). Mito-cyan fluorescent protein (CFP) or Mito-yellow fluorescent protein (YFP) was constructed by subcloning the mitochondrial presequence (the NH 2-terminal 12 amino acids of the presequence) from subunit IV of cytochrome-c oxidase into the pEGFP-N1, pECFP-N1, or pEYFP-N1 vector (Clontech). To generate green fluorescent protein (GFP), YFP, or CFP fusion proteins, full-length Kir6.2 was amplified by PCR and ligated into pEGFP-N1, pECFP-N1, or pEYFP-N1. All constructs were verified by DNA sequencing.
Cell culture and transfection. COS-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM)-F-12 supplemented with 10% fetal bovine serum, 2 mM glutamine, and penicillin-streptomycin (30) . Cells were grown on coverslips or petri dishes depending on experimental purpose. Cells were transfected with HA-tagged (Kir6.2-HA) or GFP-fused (Kir6.2-GFP) Kir6.2 and SUR2A (pCMV) K ATP channel subunits or vectors alone by using FuGENE6 (30) . Two to three days later, the cells were treated with phorbol 12-myristate 13-acetate (PMA, 100 nM), PMA plus the PKC inhibitor chelerythrine (10 M), or PMA plus the selective PKC⑀ inhibitor peptide myristoylated PKC⑀ V1-2 (PKC⑀ V1-2, 10 -20 M) for 30 -60 min before the experiments. 4␣-PMA (100 nM) was used as negative control.
Isolation of cardiomyocytes. Adult ventricular myocytes were isolated from Wistar rats (250 -300 g) by enzymatic dissociation (29, 31) . The animal procedure was approved by the Ohio State University Institutional Laboratory Animal Care and Use Committee. In brief, hearts were excised and retrogradely perfused via the aorta with oxygenated (100% O2) Tyrode solution containing (mM) 126 NaCl, 5.4 KCl, 1.0 CaCl2, 1.0 MgCl2, 0.33 NaH2PO4, 10 HEPES, and 10 glucose at 37°C. The perfusate was then changed to a Tyrode solution that was nominally Ca 2ϩ free but otherwise had the same composition. The hearts were perfused with the same solution containing collagenase for 20 min. The digested cell suspension was gently centrifuged, and the pellet was resuspended in culture medium 199 with 2% fetal bovine serum and 1% penicillin-streptomycin at 37°C. Cardiomyocytes were placed in 100-mm petri dishes and incubated at 37°C in a humidified 5% CO2-95% air mix. Cardiomyocytes were subjected to various pretreatments before mitochondrial isolation.
Preparation of mitochondria and mitoplasts. Mitochondrial fractions and total cell homogenate were prepared from cultured COS-7 cells transiently transfected with Kir6.2 and SUR2A, isolated by differential centrifugation, and further purified by 30% Percoll ultracentrifugation. Cells transfected with vector alone were always used as a negative control. For intact mitochondria or mitoplast colocalization experiments, COS-7 cells were transfected with Kir6.2-GFP and SUR2A. Both cardiomyocytes and COS-7 cells were stained with the mitochondrial marker MitoTracker (250 nM) for 15 min before fractionation. Cells after treatment were collected in an ice-cold homogenizing buffer containing (mM) 250 sucrose, 5 HEPES, and 5 EDTA, with proteinase inhibitor cocktail. Two 15-s homogenization cycles were performed on ice. The homogenate was centrifuged at 1,000 g for 10 min to remove nuclei and debris. The supernatant was centrifuged at 8,500 g for 20 min. The pellet containing the mitochondrial fraction was resuspended in the homogenizing buffer and further centrifuged at 8,500 g for 20 min. The washed mitochondria were then resuspended. For Percoll purification, the crude mitochondrial suspension (0.5 ml) was laid on the top of 10 ml of a solution containing 30% Percoll, 0.25 M sucrose, 1 mM EDTA, and 10 mM HEPES (pH 7.4). A self-generating Percoll gradient was developed by centrifugation at 95,000 g for 30 min at 4°C. The mitochondrial band was collected with a Pasteur pipette and washed in the homogenizing buffer. Mitoplasts were prepared from intact mitochondria by osmotic shock (55) . Briefly, mitochondria were subjected to osmotic shock for 5 min in hypotonic solution containing (mM) 5 sucrose, 5 HEPES, and 1 EGTA. Mitoplasts were sedimented from this solution by centrifugation at 3,920 g for 5 min and resuspended in hypertonic solution containing (mM) 750 KCl, 100 HEPES, and 1 EGTA (pH 7.2 with KOH).
Western blotting. Immunoblot analysis was carried out for the mitochondrial fraction and total cell homogenate from COS-7 cells expressing Kir6.2 and SUR2A after treatment. The purity of mitochondria was evaluated with antibody against the mitochondrial marker protein prohibitin, the plasma membrane marker Na ϩ -K ϩ -ATPase, and the endoplasmic reticulum marker calreticulin to ensure that there was no significant contamination of other membrane fractions in mitochondria. Mitochondria and total cell homogenate were denatured in a sample buffer, electrophoresed on 8 -10% SDS-polyacrylamide gels (37) , and transferred onto nitrocellulose membranes (61) . The transferred blots were blocked with 5% nonfat milk in Tris-buffered saline (TBST; 150 mM NaCl, 20 mM Tris ⅐ HCl, 0.05% Tween 20, pH 7.4) and incubated for 1 h at room temperature with the antibodies against HA epitope (Roche) or Kir6.2 or SUR2A (Santa Cruz Biotechnology) in TBST. After being washed, the blots were reacted with peroxidase-conjugated secondary antibodies (Jackson Immunuolabs) for 45 min and developed with an enhanced chemiluminescence detection system. The specificity of antibodies for Kir6.2 and SUR2A was tested by preincubation of antibodies with their antigen peptides and/or confirmed in nontransfected COS-7 cells or transfected cells with different K ATP subunit. Equal loading was confirmed by staining with Ponceau S or using antibodies against ␣-tubulin.
Immunofluorescence microscopy. Mitochondria or mitoplasts from cells after treatments were fixed with 4% formaldehyde in PBS for 30 min, blocked, permeabilized in 5% goat serum in PBS with 0.1% Triton X-100 (30 min), and labeled with primary antibody against HA tag or Kir6.2 for 2 h. Mitoplasts isolated from COS-7 cells transfected with Kir6.2-GFP/SUR2A were fixed only. Cells were washed three times and labeled with fluorescence-conjugated secondary antibody for 1 h (30). We used anti-Kir6.2 or anti-HA primary antibody for labeling KATP channel subunit Kir6.2 and the mitochondrion-specific stain MitoTracker (250 nM) for labeling mitochondria. The cells were incubated with MitoTracker for 15 min before isolation of mitochondria/mitoplasts. Immunofluorescence was visualized with a fluorescent microscope (Nikon) or a confocal scanning laser microscope (Zeiss).
FRET measurements. COS-7 cells were transfected with Kir6.2-CFP/SUR2A or Mito-YFP or cotransfected with both Kir6.2-CFP/ SUR2A and Mito-YFP. Images were acquired sequentially through CFP, YFP, and FRET filter channels. Filter sets used were the donor CFP, the acceptor YFP, and FRET. A background value was determined from a region in each image without any cells. The background value was subtracted from the raw images before FRET calculations were carried out. Corrected FRET (FRET C ) was calculated for entire images or selected regions of images, such as individual mitochondria, by using the equation Mitochondrial membrane potential. The changes in mitochondrial membrane potential (⌬⌿m) were monitored with the dye 5,5Ј,6,6Ј-tetrachloro-1,1Ј,3,3Ј-tetraethylbenzimidazolcarbocyanine iodide (JC-1) (51). Cells were treated with 4␣-PMA, PMA, PMA plus chelerythrine, or PMA plus PKC⑀ V1-2 and then stained with JC-1 (5 M) at 37°C for 15 min and rinsed three times with Tyrode solution. The mitoKATP opener diazoxide or diazoxide plus the mitoKATP inhibitor 5-hydroxydecanoic acid (5-HD) was added 20 min before the measurement. The observations were made with a fluorescence microscope. Solution changes in this protocol were made by aspirating and replacing the contents of the recording chamber. One hundred areas were selected from each image, and the average intensity for each region was quantified by MetaMorph. The ratio of JC-1 aggregate (red fluorescence) to monomer (green fluorescence) intensity for each region was calculated after background subtraction. A decrease in this ratio was interpreted as decrease of ⌬⌿ m, whereas an increase in the ratio was interpreted as gain in ⌬⌿m (62) . Cells lacking red fluorescence were considered severely damaged and were excluded from analysis.
Statistics. Group data are presented as means Ϯ SE. Unpaired t-test was used to compare between groups. Multiple group means were compared by ANOVA followed by post hoc least significant difference test. Differences with a two-tailed P Ͻ 0.05 were considered statistically significant.
RESULTS

Localization of Kir6.2 in isolated mitoplasts.
To determine whether PKC induces import of cardiac K ATP to mitochondria, we took advantage of the COS-7 cell line, which lacks native K ATP channels (33) , to deliver genes encoding cardiac K ATP channel subunits Kir6.2 and SUR2A. We first examined whether the PKC activator PMA promotes the mitochondrial import of recombinant cardiac K ATP channels. 4␣-PMA was used as a negative control. To avoid colocalization of Kir6.2 with the mitochondrial marker MitoTracker due to close apposition between Kir6.2-containing vesicles and mitochondria, we performed colocalization experiments in mitoplasts (devoid of outer membrane) freshly isolated from COS-7 cells transfected with SUR2A and Kir6.2 with GFP fused to its COOH terminus. The cells were pretreated with 4␣-PMA, PMA, or PMA plus PKC⑀ V1-2 for 60 min and were stained with MitoTracker before isolation of mitochondria. Mitoplasts were obtained by subjecting intact mitochondria to hypotonic shock (see MATERIALS AND METHODS for details). About 20 -30 images in the same treatment group (2 or 3 coverslips) from each experiment were analyzed. Three independent experiments were conducted. Without PMA (100 nM, data not shown) or with 4␣-PMA (100 nM) treatment, only a small portion of fluorescent Kir6.2 was localized in mitoplasts that were stained with MitoTracker. PMA treatment significantly increased mitoplast localization of Kir6.2 ( Fig. 1) . Quantification analysis revealed that the activation of PKC by PMA increased the number of Kir6.2-positive mitoplasts by ϳ100% ( Fig. 1C; 205.78 Ϯ 8.84% vs. 4␣-PMA, P Ͻ 0.01). To identify which PKC isozyme is involved in PKC-induced increase in mitochondrial localization of Kir6.2, we studied the effect of the selective PKC⑀ peptide inhibitor PKC⑀ V1-2. PKC⑀ has been shown to modulate K ATP channels (32) and is linked to IPC (50) . As expected, the effect of PMA on mitochondrial localization of Kir6.2 was completely prevented by PKC⑀ V1-2 (10 M; 110.39 Ϯ 10.33%). These results indicate that Kir6.2-containing K ATP channels are localized in mitochondria at low levels under normal conditions and can be enhanced by the activation of PKC isozyme PKC⑀.
FRET analysis of Kir6.2 in mitochondrial inner membrane. Although our observation that Kir6.2 is localized in mitoplasts indicates that Kir6.2 is present in mitochondrial inner membrane, there is a possibility that part of the outer membranes of mitochondria may still be attached to mitoplasts. To further define whether K ATP channels are indeed localized in mitochondrial inner membrane, we tested in COS-7 cells whether CFP fused to the COOH terminus of Kir6.2 is sufficiently close to Mito-YFP that is targeted into the mitochondrial matrix to yield FRET (24) . If K ATP channels are in the outer membrane of mitochondria, the fluorescent protein fused to the cytoplasmic domain of Kir6.2 would be exposed to the cytosol. If these channels actually reside in the mitochondrial inner membrane, their cytoplasmic domains should be exposed to the matrix enclosed by the mitochondrial inner membrane-the equivalent of the cytosol for these endosymbiotic organelles. As shown in Fig. 2, FRET C was minimal in all regions of cells that were not stimulated with PMA ( Fig. 2A) , indicating that there was no significant amount of Kir6.2 localized in mitochondria. In particular, FRET signals were not observed in the mitochondria enriched with Mito-YFP or in the Golgi area containing a large amount of Kir6.2-CFP. This validates the accuracy of our method of correction for the non-FRET component of the FRET images. Incubation of cells with PMA at 37°C for 30 -60 min led to rapid import of Kir6.2 protein into mitochondria and exhibited FRET signals due to energy transfer from CFP at the COOH terminus of Kir6.2 to YFP in the mitochondrial matrix. To compare FRET efficiencies, the FRET C was normalized to the intensity of Kir6.2-CFP after background subtraction. The FRET signal between Mito-CFP and Mito-YFP was comparable to that between Kir6.2-CFP and Mito-YFP after PMA treatment for 60 min, indicating that by then the K ATP channels targeted to the mitochondria had fully exposed the CFP at the COOH terminus of Kir6.2 to the matrix. Similar FRET signals were observed in cells expressing Mito-YFP, SUR2A, and Kir6.2 with CFP fused to its NH 2 terminus (data not shown). For dipole-dipole coupling to induce energy transfer from donor to acceptor, the fluorophore at the NH 2 or COOH terminus of Kir6.2 must be within 6 -10 nm of the fluorophore within the mitochondrial matrix (24, 48) . These findings strongly suggest that PKC activation causes insertion of Kir6.2-containing K ATP channels into the mitochondrial inner membrane.
Alterations of Kir6.2 protein in mitochondria.
To assess the effect of PKC activation on Kir6.2 protein level, immunoblot analysis was carried out for Percoll-purified mitochondria fraction and total cell homogenate prepared from COS-7 cells treated with 4␣-PMA, PMA, PMA plus chelerythrine, or PMA plus PKC⑀ V1-2 for 60 min. Enrichment of mitochondria was established by labeling with anti-prohibitin, a molecular marker of mitochondria. With anti-HA antibody, which is known as a very good antibody, a single band at 37 kDa was detected in the mitochondrial fraction as well as total cell homogenate (Fig. 3, A and B) . Anti-HA antibody did not show any nonspecific band in our study. Interestingly, the band in the mitochondrial fraction from COS-7 cells treated with PMA for 60 min exhibited a more intense signal than that from COS-7 cells without PMA treatment or with 4␣-PMA treatment. The PMA effect was significantly eliminated not only by the general PKC inhibitor chelerythrine (10 M) but also by the selective PKC⑀ inhibitor peptide PKC⑀ V1-2 (10 M). However, there was no difference in the Kir6.2 band in total cell homogenate between cells treated with 4␣-PMA and PMA. No Kir6.2 band was detected from cells without transfection. Similar results were obtained with antibody against Kir6.2 (data not shown). Figure 3B shows average Kir6.2 band intensity normalized to control from three independent experiments. PMA induces almost 100% increase in Kir6.2 protein level in the mitochondrial fraction compared with that in the control group (216.11 Ϯ 20.29%), which is consistent with the data in mitochondrial localization of Kir6.2, but has no effect on total cellular Kir6.2 protein level. When we tried a similar experiment with anti-SUR2A antibody, there was a single faint band of SUR2A at a molecular mass of 150 kDa in the mitochondrial fraction under control conditions, which was not affected by PMA pretreatment (Fig. 3C ). This result indicates that only a minimum amount of SUR2A exists in mitochondria, if there is any. However, we did not detect SUR2A with antibody against SUR2, which is similar to the report by Lacza et al. (36) showing that SUR2 was not present in mitochondria with the same antibody (purchased from the same company). This discrepancy is likely due to the differential sensitivities of two different antibodies. The specificity of anti-SUR2A antibody was confirmed in nontransfected COS-7 cells and COS-7 cells transfected with SUR2B showing no cross-reactivity with SUR2B. We noted that the anti-SUR2A antibody is very specific and more sensitive than the anti-SUR2 antibody. These results suggest that Kir6.2 is present in mitochondria and PKC⑀ activation by PMA further increases Kir6.2 protein level in mitochondria. This increase may not be due to increased protein synthesis for Kir6.2 since Kir6.2 in the total cellular fraction was not changed after PMA treatment.
Kir6.2-dependent changes in mitochondrial membrane potential.
To determine whether Kir6.2-containing K ATP channels in mitochondria are functional, we measured the changes in ⌬⌿ m in intact COS-7 cells transfected with Kir6.2 and SUR2A, using the potential-sensitive dye JC-1. About 100 regions were selected from each image, which contains 10 -20 cells, and 5 images were taken from each well. Three independent experiments were conducted, and each experiment had triplicate wells of the same treatment. The average intensity for each image was quantified after background subtraction. The green fluorescence of monomer indicates low potential (depolarized), and the red fluorescence of J-aggregate indicates high potential (hyperpolarized). Since K ATP channels are usually not active because of inhibition by matrix ATP, the mitochondrionselective K ATP opener diazoxide was used to activate K ATP in mitochondria. Diazoxide has been shown to confer the cardioprotection of IPC by selectively activating mitoK ATP channels (22, 47, 67) . If Kir6.2/SUR2A-containing K ATP channels are localized in mitochondrial inner membrane and involved in the protection of IPC, this channel is expected to be sensitive to activation by diazoxide. The K ATP -dependent changes were verified by the mitochondrial K ATP -selective inhibitor 5-HD. In the absence of diazoxide, the JC-1 ratio (J-aggregate/monomer) in cells pretreated with PMA for 60 min was not significantly different from the control cells pretreated with 4␣-PMA (Fig. 4B ). However, diazoxide (100 M), within 15 min of application, decreased the JC-1 ratio significantly in PMAtreated cells (potential decreased, green fluorescence increased; Fig. 4A ) compared with that in 4␣-PMA-pretreated cells with diazoxide ( Fig. 4; 53 .04 Ϯ 10.22% vs. 97.87 Ϯ 9.24%, PMAϩdiazoxide vs. 4␣-PMAϩdiazoxide, P Ͻ 0.01). When diazoxide was added to the solution 5 min after the application of 5-HD, the diazoxide-induced decrease in ⌬⌿ m in cells treated with PMA was inhibited not only by 5-HD (500 M; 83.79 Ϯ 6%) but also by pretreatment with PKC⑀ V1-2 (20 M; 82.61 Ϯ 4.56%). Either 5-HD application or PKC⑀ V1-2 pretreatment alone did not have any effect on ⌬⌿ m (data not shown). These data show that ⌬⌿ m in cells pretreated with PMA was not different from that in cells with 4␣-PMA but could be decreased by activation of K ATP channels in mitochondria with the mitoK ATP opener diazoxide after PMA pretreatment, an effect that was inhibited by the mitoK ATP inhibitor 5-HD. Furthermore, the diazoxide effect in PMAtreated cells was not seen in nontransfected COS-7 cells, indicating that the effect of diazoxide on ⌬⌿ m was due to activation of Kir6.2-containing K ATP channels in mitochondrial inner membrane. The finding that diazoxide induces K ATP -dependent depolarization of ⌬⌿ m after activation of PKC⑀ by PMA pretreatment but not in the control group with 4␣-PMA treatment suggests that K ϩ influx caused by diazoxide under basal conditions may not be sufficient to cause significant changes in ⌬⌿ m under our experimental conditions. This result does not exclude the possibility that other mitochondrial functions may be altered by diazoxide under normal conditions or in isolated mitochondria where no translocation occurs. Furthermore, the observation that PMA pretreatment alone did not change ⌬⌿ m suggests that K ATP channels in mitochondrial inner membrane are normally inhibited by matrix ATP even though PMA may increase the number of functional Kir6.2-containing K ATP channels in mitochondria. It should be noted that PMA was used only for pretreatment and was washed out before measurement of ⌬⌿ m with diazoxide.
Localization of Kir6.2 in isolated mitochondria from cardiomyocytes.
To exclude the possibility that overexpression of recombinant K ATP channels contributes to our findings, we performed similar colocalization experiments in isolated mitochondria from rat adult cardiomyocytes. Because of very tightly packed myofibrils around mitochondria and other organelles in cardiomyocytes, it is very difficult to study subcellular localization of membrane proteins in isolated cardiomyocytes. We therefore performed colocalization experiments in isolated mitochondria. Cardiomyocytes were subjected to pretreatment with 4␣-PMA, PMA, or PMA plus PKC⑀ V1-2 for 60 min before mitochondrial isolation. To avoid bias in our analysis, 30 images were randomly collected from the triplicates of the same treatment in each independent experiment. Two to five independent experiments depending on treatments were conducted, and ϳ1,000 mitochondria were counted for statistical analysis. Anti-Kir6.2 antibody was used to detect native Kir6.2 protein. As Fig. 5A shows, PMA increased mitochondrial localization of Kir6.2, as indicated by increased yellow staining in the merged image. The pretreatment of PMA alone with PKC⑀ V1-2 blocked the PMA effect. Quantitative analysis by normalizing Kir6.2-positive mitochondria to the control without PMA treatment showed that PMA significantly increased the number of Kir6.2-positive mitochondria ( Fig. 5B ; 240.31 Ϯ 13.6% vs. 4␣-PMA, P Ͻ 0.01). This PMA effect was almost completely prevented by pretreatment with the PKC inhibitor chelerythrine (10 M; data not shown) as well as the selective PKC⑀ inhibitor peptide PKC⑀ V1-2 (10 M; 120.02 Ϯ 9.77% vs. PMA group, P Ͻ 0.01). These results are consistent with our observation in COS-7 cells transiently transfected with Kir6.2/SUR2A and support the scenario that Kir6.2-containing K ATP channels are localized in mitochondria and this mitochondrial localization was further enhanced by PKC activation.
DISCUSSION
The present study points to a novel trafficking mechanism for dynamic regulation of K ATP channel number: PKC-induced import of K ATP channels into mitochondria. We show that the K ATP channel pore-forming subunit Kir6.2 is localized in mitochondria, using both cardiomyocytes and K ATP channeldeficient COS-7 cells transiently transfected with Kir6.2 and SUR2A. Most importantly, we demonstrate that activation of PKC isozyme PKC⑀ significantly increases the number of functional Kir6.2-containing K ATP channels in mitochondrial inner membrane, possibly by promoting import of Kir6.2 to mitochondria from cytosol. One likely scenario is that K ATP channels are simultaneously targeted to not only cell surface but also mitochondrial inner membrane after their synthesis in the cytosol and PKC activation enhances the import of these channels to mitochondria. The specific pharmacological and biophysical properties of K ATP channels at the plasma membrane and mitochondrial inner membrane may differ depending on the environment in which they reside and the regulatory factors with which they are associated (16) .
The function of ion channels depends critically on not only channel activity but also the number of functional channels. Our observation that activation of PKC⑀ by PMA increases http://ajpheart.physiology.org/ mitochondrial localization of Kir6.2-containing K ATP channels points out a novel trafficking mechanism in regulation of K ATP channel function. However, this finding does not exclude the possibility that PKC may directly interact with the channel. Actually, PMA has been shown to activate cell surface Kir6.2/ SUR2A-containing K ATP channels (29, 40) as well as mitoK ATP channels (32) . Under our experimental conditions, PMA was washed out before we tested diazoxide-induced changes in ⌬⌿ m . If there is any residue of PMA, it may not be enough to activate K ATP channels and cause alterations in ⌬⌿ m . The present study mainly attempted to address whether K ATP channels translocated by PKC activation are functional.
Our data and that of others (15, 36, 56, 74) show that there is a basal level of Kir6.2-containing K ATP channels in mitochondria. It is therefore likely that K ϩ channel openers or stimulators such as PMA may directly activate these channels under normal conditions or in isolated mitochondria where no translocation occurs. In the present study, diazoxide alone did not change ⌬⌿ m in control cells without PMA or pretreated with 4␣-PMA. One explanation is that K ϩ influx induced by diazoxide in COS-7 cells may not be high enough to cause significant changes in ⌬⌿ m but may produce changes in other mitochondrial functions that we did not measure, such as matrix volume. On the other hand, our observation that diazoxide caused changes in ⌬⌿ m after PMA treatment indicates that the K ATP channels translocated by PMA are functional by increasing K ϩ influx. However, our data do not imply that the same functional consequence in mitochondria (⌬⌿ m ) caused by diazoxide-induced opening of K ATP channels would occur in native cardiomyocytes. We employed COS-7 cells with expressed recombinant K ATP channels, which may be different from cardiomyocytes in terms of the extent of K ϩ influx. We therefore do not believe that our data conflict with that of others showing no significant changes in ⌬⌿ m by diazoxideinduced opening of mitoK ATP (14, 35) from isolated heart mitochondria. Nevertheless, the purpose of the JC-1 experiment was not to define ultimate changes in mitochondrial function by diazoxide but rather to study whether the translocated Kir6.2-containing K ATP channels are functional. Diazoxide was used as a tool to activate K ATP channels since K ATP channels are normally inactive.
Although it is generally assumed that the Kir6.2/SUR2A-containing K ATP channel is localized exclusively at the sarcolemma, there is evidence that Kir6.2 or SUR2A is present in mitochondria. Several groups have reported that Kir6.2 has been found more or less in isolated heart mitochondria (15, 36, 56, 74) . One study has reported that Kir6.2 is not part of the components of mitoK ATP channels in the rabbit heart (53) . The discrepancy may be due to the relatively low level of Kir6.2-containing K ATP channels in mitochondria under normal conditions. The technical difficulties in dissecting a small amount of membrane-targeted proteins localized in mitochondria with conventional immunofluorescence microscopy may contribute to the inconsistency, especially in adult cardiomyocytes with tightly packed myofibrils and suborganelles. Differential sensitivity of antibodies against individual K ATP subunits may also likely be a reason for the discrepancy. With regard to the SUR subunit, less is known about its presence in mitochondria because of the difficulty in getting antibody specific to SUR2A or SUR2B. We tested anti-SUR2A antibody, recently available commercially, and found a faint band of SUR2A present in mitochondria of COS-7 cells by Western blot, which is consistent with some reports (15, 56) . Similar to another study (36), we did not detect a SUR2 band with anti-SUR2 antibody in mitochondria. Because of the lack of series of studies with different approaches, we cannot make a conclusion at the present time that SUR2A is indeed localized in mitochondria.
The contribution of Kir6.1 to mitoK ATP channels is also under debate (42, 57) . The Kir6.1/SUR2B-based channels do not exhibit sensitivity to the inhibition by intracellular ATP (70) , whereas the mitoK ATP channels recorded in mitochondria inner membrane from liver and reconstituted lipid bilayer from purified heart mitochondria are very sensitive to ATP, a characteristic feature of the K ATP channel pore-forming subunit Kir6.2 (17) . Although Kir6.1 protein level was increased by ischemia, this only occurred after prolonged ischemia (60 min of ischemia followed by 24 -72 h of reperfusion). Sublethal ischemia (15-30 min followed by 24 h of reperfusion), which is equivalent to the time course of PMA treatment in the present study, did not induce Kir6.1 expression (3). It is therefore less likely that Kir6.1 would contribute to functional mitoK ATP channels even though it was found in mitochondria (57) . Furthermore, knockout of Kir6.1 gene in intact mice does not disrupt mitoK ATP opening (42) . Nevertheless, the present study focuses on the regulatory mechanism of Kir6.2-containing K ATP channels in mitochondria and does not exclude the possibility that other protein(s) may form the part of K ATP channel complex in mitochondria.
The dual distribution at both plasma membrane and mitochondria has been reported for other ion channel proteins, such as Kv1.3 (59), the Ca 2ϩ -activated BK potassium channels (55), the voltage-dependent anion channels (9, 19) , and connexin43 (10, 39) . Interestingly, connexin43 in mitochondria has recently been shown to be increased by IPC, possibly through phosphorylation (10) . These channels lack the NH 2 -terminal mitochondrial targeting sequence but are targeted to mitochondrial inner membrane by unknown mechanisms. Many mitochondrial proteins of the inner membrane such as mitochondrial carriers lack the NH 2 -terminal targeting sequence but instead contain sorting and targeting information throughout the mature protein, which is hardly recognizable (11, 18) . The targeting information seems to comprise several distant amino acids spread throughout the entire protein (63) . Similarly, Kir6.2 does not exhibit a classic NH 2 -terminal mitochondrial targeting presequence according to the prediction from TargetP (21) and may contain unidentified internal targeting sequences. Although specific posttranslational protein modifications and differential splicing have been hypothesized to account for organelle protein targeting, the mechanisms responsible for the simultaneous targeting of a protein to different cellular compartments are not known and are beyond the focus of the present study.
Import of most nucleus-encoded proteins into mitochondria is highly regulated and mediated by mitochondria targeting sequence with the aid of a handful of distinct complexes including molecular chaperones (34) . Both heat shock protein (HSP)70 and HSP90, which are linked to cardioprotection, have been shown to facilitate mitochondrial protein import to mitochondria (38, 63-65, 71, 72) . HSP90 and HSP70 specifically interact with the mitochondrial protein import receptor TOM70 at the outer membrane and are required for translocation of precursor proteins. Furthermore, PKC has been shown to be involved in HSP-mediated cardioprotection (13, 68) . The present finding points to an important mechanism in Kir6.2-containing K ATP channel-mediated cardioprotection: PKC⑀-induced mitochondrial import. It should be noted that the present study was not aimed at defining the molecular identity of putative mitoK ATP but rather at studying the regulatory mechanism involved in Kir6.2-containing K ATP channel trafficking. This observation does not exclude the possibility that a distinct mitoK ATP or other K ATP component(s) in mitochondria may exist. It has been reported that succinate dehydrogenase may be a part of a mitoK ATP macromolecular supercomplex that contributes to cardioprotection (5) . A Ca 2ϩ -activated K ϩ channel has also been found in mitochondrial inner membrane and linked to cardioprotection (69) .
The evidence supporting a protective role for the Kir6.2-containing K ATP channels has been provided by studies using K ATP -deficient COS-7 cells and Kir6.2-knockout mice. By cotransfection of Kir6.2/SUR2A genes, Jovanovic et al. (33) demonstrated that delivery of Kir6.2 and SUR2A genes into COS-7 cells resulted in protection against hypoxia-reoxygenation injury as a result of inhibition of intracellular Ca 2ϩ loading. Studies in Kir6.2-knockout mice (28, 58) showed a failure of IPC to reduce infarct size and preserve contractile recovery in Kir6.2-deficient mice. The activation of PKC has also been linked to cardioprotection (50) and K ATP channels (40, 66) . A number of possibilities have been suggested as to how opening the mitoK ATP results in cardioprotection, such as reduced Ca 2ϩ overload in mitochondria by depolarizing ⌬⌿ m , mild uncoupling and reduced free radical production, and moderate swelling and increased ATP production (14) .
It is known that movement of key proteins into mitochondria during apoptosis is essential for the regulation of apoptosis (12) . Mitochondria are increasingly recognized as key players in cell survival (25) . Most of the mitochondrial proteins are nuclear encoded, synthesized in the cytosol, and transported to mitochondria by translocases (34, 41, 49) . Given that mitochondria are a critical site for cardioprotection, our observations indicate that the dynamic regulation of protein trafficking to mitochondria represents a novel mechanism in cardioprotection of IPC.
